AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Claims 1-52 (Canceled)

53. (new) A sustained-release dosage form, comprising oxymorphone or a salt thereof, a hydrophilic polymer, a binder, and a diluent.

54. (new) The sustained-release dosage form of claim 53, wherein the dosage form contains granules having a diameter from about 0.1 mm to about 3 mm.

55. (new) The sustained-release dosage form of claim 53, further comprising an alkylcellulose.

56. (new) The sustained-release dosage form of claim 53, further comprising ethylcellulose.

57. (new) The sustained-release dosage form of claim 53, wherein the dosage form is in the form of a tablet.

58. (new) The sustained-release dosage form of claim 53, wherein the dosage form is in the form of a capsule.

59. (new) The sustained-release dosage form of claim 53, wherein the dosage form is in the form of a matrix.

60. (new) The sustained-release dosage form of claim 53, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

61. (new) The sustained-release dosage form of claim 53, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

62. (new) A sustained-release dosage form, made by the process comprising:

(a) mixing oxymorphone or a salt thereof with a hyrodrophilic polymer, a binder, and a diluent;

(b) subjecting the mixture to shear to form granules; and

(c) incorporating the granules into a dosage form.

63. (new) The process of claim 62, wherein the granules have a diameter from about 0.1 mm to about 3 mm.

64. (new) The process of claim 62, wherein step (c) comprises incorporating the granules into a tablet.

65. (new) The process of claim 62, wherein step (c) comprises incorporating the granules into a capsule.

66. (new) The process of claim 62, wherein the dosage form is a matrix.

67. (new) The process of claim 62, wherein step (a) further comprises mixing oxymorphone or a salt thereof with an alkylcellulose.

68. (new) The process of claim 62, wherein step (a) further comprises mixing oxymorphone or a salt thereof with ethylcellulose.

69. (new) The process of claim 62, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

70. (new) The process of claim 62, wherein the dosage form provides a therapeutic effect for about 24 hours or more.

71. (new) A process of making a sustained-release dosage form comprising:

(a) mixing oxymorphone or a salt thereof with a hydrophilic polymer, a binder, and a diluent;

(b) subjecting the mixture to shear to form granules; and

(c) incorporating the granules into a dosage form.

72. (new) The process of claim 72, wherein the granules have a diameter from about 0.1 mm to about 3 mm.

73. (new) The process of claim 72, wherein step (c) comprises incorporating the granules into a tablet.

74. (new) The process of claim 72, wherein step (c) comprises incorporating the granules into a capsule.

75. (new) The process of claim 72, wherein the dosage form is a matrix.

76. (new) The process of claim 72, wherein step (a) further comprises mixing oxymorphone or a salt thereof with alkylcellulose.

77. (new) The process of claim 72, wherein step (a) further comprises mixing oxymorphone or a salt thereof with ethylcellulose.

78. (new) The process of claim 72, wherein the dosage form provides a therapeutic effect for about 12 hours or more.

79. (new) The process of claim 72, wherein the dosage form provides a therapeutic effect for about 24 hours or more.